50% Hemolysis Rate Hemolysin Test (CH50 Assay): Principle, Methodology, and Applications

The 50% hemolysis rate hemolysin test, widely known as the CH50 assay, is the reference method for quantifying the total functional activity of the classical complement pathway in serum. By measuring the dilution of test serum that lyses exactly half of a standardized suspension of hemolysin-sensitized sheep erythrocytes, the assay provides a sensitive and clinically meaningful index of complement integrity. This article explains the scientific principle, sample requirements, testing items, step-by-step methodology, and typical applications of the 50% hemolysis hemolysin test performed in accredited third-party laboratories.

Technical Overview

The 50% hemolysis rate hemolysin test is a functional bioassay that evaluates the hemolytic capacity of the complement system, a group of sequentially activated serum proteins that form a central effector arm of innate immunity. In the assay, sheep red blood cells (SRBC) are coated with hemolysin, a rabbit anti-sheep erythrocyte antiserum also referred to as amboceptor. When complement-containing test serum is added, the antigen-antibody complex on the erythrocyte surface activates the classical complement pathway, generating the membrane attack complex (C5b-9) that punctures the cell membrane and releases hemoglobin. The quantity of hemoglobin released, measured spectrophotometrically, is directly proportional to the degree of complement-mediated lysis.

The 50% endpoint is deliberately chosen because the complement dose-response curve follows the von Krogh sigmoid relationship, and the curve is steepest at the point of 50% hemolysis. At this inflection point, a small change in complement concentration produces the largest measurable change in lysis, giving the assay its maximal analytical sensitivity and precision. The result is conventionally reported as CH50, defined as the reciprocal of the highest serum dilution that produces 50% lysis of the standardized erythrocyte suspension, expressed in units per milliliter (U/mL).

The test is applicable to human clinical diagnostics, preclinical animal studies, and the biocompatibility and immunotoxicity evaluation of pharmaceuticals, biological products, and medical devices. Methodological harmonization with recognized frameworks such as ISO 10993-4 (tests for blood interaction, including complement activation) and established clinical laboratory practice ensures that results are comparable and defensible across study contexts.

Testing Samples

Human Serum Samples

Venous blood is collected into plain tubes without anticoagulant, allowed to clot at room temperature, and centrifuged promptly to separate serum. Serum is the preferred matrix because calcium-dependent classical pathway activation proceeds optimally in this specimen type. Samples are stored frozen at -70°C or below and protected from repeated freeze-thaw cycles, which progressively degrade complement activity and artificially lower CH50 values.

Animal Serum Samples

Serum from rodent, canine, primate, and other preclinical species is routinely tested during toxicology studies and biologics development. Species-specific reference ranges and incubation parameters are established during method validation because complement kinetics and thermal stability differ between species.

Pharmaceutical and Biological Product Samples

Nanomedicines, monoclonal antibodies, intravenous lipid formulations, contrast agents, and biomaterial extracts can be incubated with standardized human or animal serum to assess whether the product activates or consumes complement. Complement activation by such products is a recognized safety concern within the ISO 10993-4 evaluation framework.

Control and Reference Materials

Each run includes a pooled normal serum calibrator with an assigned CH50 potency, complement-inactivated serum as a negative control, and sensitized erythrocytes lysed with water or hypotonic buffer as the 100% hemolysis control. These materials anchor the standard curve and validate run performance.

Testing Items

Core testing items available under the 50% hemolysis hemolysin test portfolio typically include:

• Total classical pathway complement activity (CH50, U/mL)
• Alternative pathway hemolytic activity (AH50) for pathway discrimination
• Hemolysin potency and minimal hemolytic unit (MHU) titer determination
• Residual complement activity after product incubation (complement consumption assay)
• Complement fixation test indicator system performance verification
• Serum hemolytic activity in longitudinal pharmacology and toxicology monitoring

Testing Methods

Reagent Preparation and Erythrocyte Sensitization

Sheep erythrocytes are washed in veronal-buffered saline containing calcium and magnesium ions and standardized photometrically to a fixed cell concentration. Hemolysin is titrated in advance and used at an optimal sensitizing dose, commonly two to five minimal hemolytic units, to coat the erythrocytes. Over- or under-sensitization shifts the assay window and is strictly controlled.

Incubation and Hemolysis Reaction

Serial dilutions of test serum are prepared in ice-cold buffered diluent and mixed with the sensitized erythrocyte suspension. Reaction mixtures are incubated at 37°C for a validated interval, typically 30 to 60 minutes, to allow complement activation and hemolysis to reach completion. Unlysed cells are removed by centrifugation, and the hemoglobin content of each supernatant is measured by absorbance at approximately 540 to 541 nm.

Calculation of the CH50 Endpoint

Fractional lysis for each dilution is calculated against the 0% (buffer blank) and 100% (complete lysis) controls. The data are linearized using the von Krogh transformation, plotting the logarithm of the ratio of lysed to non-lysed cells against the logarithm of serum concentration. The interpolated 50% endpoint yields the CH50 value in U/mL, with typical adult human reference intervals established by each laboratory, commonly in the range of approximately 30 to 75 U/mL.

Quality Control and Acceptance Criteria

Acceptable runs require the calibrator to recover within pre-assigned limits, control sera to fall within established confidence intervals, and replicate coefficient of variation to remain within the validated threshold, typically below 15%. Visibly hemolyzed, lipemic, or repeatedly frozen-thawed specimens are rejected because they compromise the optical measurement and degrade complement integrity.

Applications

Clinical Immunology and Diagnostics

The CH50 assay screens for inherited complement component deficiencies, monitors complement consumption in systemic lupus erythematosus, immune complex disease, cryoglobulinemia, and post-infectious glomerulonephritis, and supports the workup of recurrent infections and hereditary angioedema. A markedly reduced or absent CH50 directs further component-specific testing.

Pharmaceutical and Medical Device Safety Evaluation

Complement activation-related infusion reactions, including cardiopulmonary distress after administration of certain nanomedicines and biologicals, are important safety endpoints. CH50-based functional assays complement biomarker panels such as C3a, C5a, Bb, and SC5b-9 within ISO 10993-4 blood-interaction evaluations and during comparability and immunotoxicity studies of pharmaceutical candidates.

Preclinical and Research Studies

The assay supports immunotoxicity assessments in animal models, investigation of complement-modulating therapeutics, vaccine adjuvant research, and serological method development, including performance verification of the hemolysin indicator system used in complement fixation testing.

FAQ

Why is the endpoint set at 50% hemolysis rather than complete hemolysis?

Because the complement dose-response curve is sigmoidal, the 50% point lies on the steepest segment of the curve, where lysis changes most sharply per unit change in complement activity. This maximizes analytical sensitivity and minimizes measurement error compared with total lysis endpoints.

How should samples be collected and shipped?

Collect blood into clot-activating tubes, allow clotting, centrifuge promptly, and freeze the separated serum at -70°C or colder. Ship on dry ice with temperature monitoring. Never submit grossly hemolyzed samples or samples subjected to repeated freeze-thaw cycles.

What does a low CH50 result indicate?

A decreased CH50 suggests complement consumption or deficiency, seen in autoimmune immune complex disease, active glomerulonephritis, sepsis, cryoglobulinemia, hepatic synthetic failure, or inherited component deficiency. Interpretation should always be paired with clinical context and, where needed, individual complement component assays.

How does CH50 differ from AH50?

CH50 measures the classical pathway using hemolysin-sensitized sheep erythrocytes in the presence of calcium and magnesium, while AH50 measures the alternative pathway using unsensitized rabbit erythrocytes with magnesium and EGTA to chelate calcium. Comparing both results helps localize the pathway affected.

Can this assay evaluate whether a product activates complement?

Yes. By incubating the test article with pooled normal serum and then measuring residual CH50, or by pairing CH50 with split-product biomarkers, laboratories can determine whether a pharmaceutical, biological, or material extract consumes or activates complement under standardized conditions.